{
    "organizations": [],
    "uuid": "c7f81ffde6cba5c3dfb75d575954098f625b9165",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ligand-pharma-says-underreported-p/brief-ligand-pharma-says-underreported-potential-aggregate-milestone-payments-related-to-license-agreement-with-roivant-sciences-idUSFWN1QP087",
    "ord_in_thread": 0,
    "title": "BRIEF-Ligand Pharma Says‍ Underreported Potential Aggregate Milestone Payments Related To License Agreement With Roivant Sciences",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 7 (Reuters) - Ligand Pharmaceuticals Inc:\n* LIGAND PHARMACEUTICALS SAYS‍ UNDERREPORTED POTENTIAL AGGREGATE MILESTONE PAYMENTS RELATED TO LICENSE AGREEMENT WITH ROIVANT SCIENCES FOR LGD-6972​\n* LIGAND PHARMA SAYS UNDER AGREEMENT, CO TO RECEIVE POTENTIAL LICENSE & MILESTONE PAYMENTS OF UP TO $548.8 MILLION - SEC FILING Source text: ( bit.ly/2I7Qw0U ) Further company coverage:\n ",
    "published": "2018-03-07T19:26:00.000+02:00",
    "crawled": "2018-03-08T17:21:20.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "ligand",
        "pharmaceutical",
        "inc",
        "ligand",
        "pharmaceutical",
        "underreported",
        "potential",
        "aggregate",
        "milestone",
        "payment",
        "related",
        "license",
        "agreement",
        "roivant",
        "science",
        "ligand",
        "pharma",
        "say",
        "agreement",
        "co",
        "receive",
        "potential",
        "license",
        "milestone",
        "payment",
        "million",
        "sec",
        "filing",
        "source",
        "text",
        "company",
        "coverage"
    ]
}